RxDoctor Payments Data

Cortny Brookover

Gerontology · Canton, OHNPI 1992470025

Payments from drug & device makers

$1,477in general payments, 2019–2025

Across 53 payments — averaging $27.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$360
  • Sumitomo Pharma America, Inc.$221
  • Astellas Pharma US Inc$190
  • Merck$108
  • AbbVie$103
  • Medtronic$83
  • plus $412 from 11 others

What the payments were for

  • Food & beverage$1,28787%
  • Education$19013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Convatec Inc.10$360
Sumitomo Pharma America, Inc.10$221
Astellas Pharma US Inc2$190
Merck4$108
AbbVie5$103
Medtronic3$83
Urogen Pharma, Inc.3$82
Tolmar, Inc.4$73
Immunitybio, Inc.3$72
Cycle Pharmaceuticals Inc2$46
Hollister Incorporated1$25
Teleflex LLC1$23
Johnson & Johnson1$22
Laborie Medical Technologies Corp.1$21
Vertex1$19
Coloplast1$14
Urovant Sciences Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,477 in reported general payments places this provider in the 75th percentile of 361 gerontology providers in Ohio.

See all gerontology providers in Ohio

Medicare billing

Part B allowed, 2024
$26,645
Medicare patients
261
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron276$138,679
GemtesaVibegron52$35,419
Tamsulosin Hcl678$9,976
Potassium Citrate ErPotassium Citrate43$4,081
Finasteride294$3,829
Dutasteride59$3,510
Methenamine Hippurate32$2,815
Trospium Chloride55$2,691
Oxybutynin Chloride ErOxybutynin Chloride63$2,109
Silodosin17$1,466
Cephalexin120$1,066
Alfuzosin Hcl ErAlfuzosin Hcl38$633
Doxazosin Mesylate43$466
Solifenacin Succinate28$394
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim77$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$190$138,679276 claims
Sumitomo Pharma America, Inc.Gemtesa$221$35,41952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 gerontology providers in Ohio.

Other gerontology in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →